Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

July 31, 2006

Conditions
Essential Hypertension
Interventions
DRUG

olmesartan alone or in combination with hydrochlorothiazide

Trial Locations (32)

106

Pfizer Investigational Site, Taipei

112

Pfizer Investigational Site, Taipei

333

Pfizer Investigational Site, Guei-Shan Shiang

813

Pfizer Investigational Site, Kaohsiung City

10400

Pfizer Investigational Site, Khet Rajathevee

Pfizer Investigational Site, Bangkok

10430

Pfizer Investigational Site, Jakarta

10700

Pfizer Investigational Site, Bangkok

11420

Pfizer Investigational Site, Jakarta

34390

Pfizer Investigational Site, Haseki/Istanbul

35100

Pfizer Investigational Site, Bornova/Izmir

50200

Pfizer Investigational Site, Chiang Mai

60286

Pfizer Investigational Site, Surabaya

70300

Pfizer Investigational Site, Seremban

93586

Pfizer Investigational Site, Kuching

119074

Pfizer Investigational Site, Singapore

169608

Pfizer Investigational Site, Singapore

Unknown

Pfizer Investigational Site, Medellín

Pfizer Investigational Site, Barranquilla

Pfizer Investigational Site, Cartagena

Pfizer Investigational Site, Bogota

Pfizer Investigational Site, Santiago de Cali

Pfizer Investigational Site, Escobedo

Pfizer Investigational Site, Quito

Pfizer Investigational Site, NT

Pfizer Investigational Site, Shatin, NT

Pfizer Investigational Site, Jakarta

Pfizer Investigational Site, San Juan City

Pfizer Investigational Site, Quezon

Pfizer Investigational Site

06100

Pfizer Investigational Site, S¿hhiye/Ankara

Pfizer Investigational Site, Sihhiye/Ankara

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY